Intermittent versus continuous androgen suppression for prostatic cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  De Conti, Paulo D ^a   Atallah, A N ^b   Arruda, H ^b   Soares, B G O ^b   El Dib, R P ^b   Wilt, T J ^b  

^a NONE   (Brazil)

^b NONE

Author keywords

*Orchiectomy; Androgen antagonists * administration dosage ; Drug administration schedule; Neoplasm staging; Prostate specific antigen blood ; Prostatic neoplasms blood; pathology; *therapy ; Randomized controlled trials as topic

Indexed keywords

BUSERELIN; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; TRIPTORELIN;

ALCOHOL INTOLERANCE; ANEMIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DATA EXTRACTION; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLEASON SCORE; GYNECOMASTIA; HOT FLUSH; HUMAN; METASTASIS; MONOTHERAPY; NAUSEA; ORCHIECTOMY; OUTCOME ASSESSMENT; PROSTATE CANCER; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; VISUAL DISORDER; VOMITING;

EID: 44949231272     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005009.pub2     Document Type: Review

References (48)

1. Calais 2002 {published data only} Calais F, Bono A, Wkealan P. Phase III study of intermittent MAB versus continuous MAB international cooperative study. Eur Urol 2002;419(Suppl):A 531.
2. de Leval 2002 {published data only} de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clinical Prostate Cancer 2002;1(3):163-71.
3. EAU TULP 2002 {published data only} Schasfoort E, Heathcote P, Lock T, Zerbib M, Newling D. Intermittent androgen suppression in the treatment of advanced prostate cancer. EAU TULP 2002.
4. Hering 2000 {published data only} Hering F, Rodrigues PRT, Lipay MA, Nesrallah L, Srougi M. Metastatic adenocarcinoma of the prostate: comparation between continuos and intermittent hormonal treatment. Braz J Urol 2000;26:276-82.
5. Yamanaka 2005 {published data only} Yamanaka H, Ito K, Naito S, Tsukamoto T, Usami M, Fujimoto H. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate 2005;63(1):56-64.
6. Bouchot 2000 Bouchot O, Lenormand L, Karan G, Prunet D, Gaschignard N, Malinovsky JM, et al.Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000;38:543-9.
7. Crook 1999 Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999;53:530-4.
8. De La Taille 2003 De La Taille A, Zerbid M, Conquy S, Amsellem-Quazana D, Thiounn N, Flan TA, et al.Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003;91:18-22.
9. Goldenberg 1995 Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45:839-44.
10. Goldenberg 1999 Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical Experience: with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol Urol 1999;3(3):287-292.
11. Grossfeld 2001 Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001;58:240-245.
12. Gulley 2005 Gulley JL, Figg WD, Steinberg SM, Carter J, Hussain MH, Dahut WL. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen depreivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. The Journal of Urology 2005;173:1567-1571.
13. Higano 1996 Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996;48:800-4.
14. Horwich 1998 Horwich A, Huddart RA, Gadd J, Boyd PJ, Hetherington JW, Whelan P, et al.A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998;81:96-9.
15. Hussain 2006 (SWOG) Hussain M, Tangen CM, Higano C, Schelhammer P, Faulkner J, Crawford ED, et al.Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology 2006;24(24):3984-90.
16. Klotz 1986 Klotz LH, Herr HW, Morse MJ, Whitmore WF. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;587:2546-50.
17. Klotz 1998 Klotz LH, Crook JM, Amitage GR, Saskatoon SK, Gleave ME, Goldenberg L. A phase II study of intermittent androgen suppression (IAS) in men with a rising serum PSA after radiation for localized prostate cancer. J Urol 1998;159(5):335.
18. Klotz 2005 Klotz L, Correia A, Zhang W. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer and Prostatic Diseases 2005;8(2):179-83.
19. Kurek 1999 Kurek R, Renneberg H, Lübben G, Kienle E, Tunn UW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35((Suppl 1)):27-31.
20. Lane 2004 Lane TM, Ansell W, Farrugia D, Wilson P, Williams G, Chinegwundoh F, Philp T, Hines J, Oliver RTD. Long-Term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004;73:117-122.
21. Mottet 1999 Mottet N, Costa P, Navratil H. Intermittent versus continuous hormone deprivation in metastatic prostate cancer: preliminary data from an ongoing European study. Prostate Cancer and Prostatic Diseases 1999;2(52):S2-S4.
22. Oliver 1997 Oliver RT, Willians G. Paris AM, Blandy JP. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 1997;49:79-82.
23. Sato 2004 Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, and The Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 2004;64:341-345.
24. Sciarra 2000 Sciarra A, Di Chiro C, Di Silverio F. Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer. World J Urol 2000;18:392-400.
25. Strum 2000 Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 2000;5:45-52.
26. Theyer 1998 Theyer G, Hamilton G. Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology 1998;52:353-9.
27. NCIC CTG (PR-7) Ongoing study Starting date of trial not provided. Contact author for more information.
28. SWOG 9346 Ongoing study Starting date of trial not provided. Contact author for more information.
29. Takeda EC 210 Ongoing study Starting date of trial not provided. Contact author for more information.
30. Tunn 1996 Ongoing study Starting date of trial not provided. Contact author for more information.
31. ACS 2006 American Cancer Society [online] Atlanta. Available from URL: http://cancer.org 2006.
32. Akakura 1993 Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermitent androgen supression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993; Vol. 71:2782-90.
33. Altman 1996 Altman DG, Bland JM. Detecting skewness fron summary information. BMJ 1996;313(7066):1200.
34. Bladou 1996 Bladou F, Vessella RL, Buhler KR, et al.Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J. Cancer 1996;67:785-790.
35. Bruchovsky 1990 Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275-82.
36. Bruchovsky 1998 Bruchovsky N, Klotz LH, Crook JM, Armitage GR, Gleave ME, Goldenberg SL. Aphase II study of intermittent androgen suppression (IAS) in men with a rising serum PSA after radiation for localized prostate cancer. J Urol 1998;158((5 Suppl)):1287.
37. Carneiro 1999 Carneiro C Da Silva. Phase III study on intermittent MAB vs contínuos MAB: an international co-operative study. Prostate Cancer Prostatic Dis 1999;2:(S3):S9.
38. Castro 1997 Castro AA, Clark OA, Atallah AN. Optimal Search Strategy for Clinical Trials in the Latin American and Caribbean Health Science Literature Database (LILACS). São Paulo Medical Journal 1997;115(5):423-426.
39. Clarke 2003 Clarke M, Oxman AD, editors. Selection bias. Cochrane Reviewers' Handbook 4.1.6 [updated January 2003]. Section 6.3 In The Cochrane Library 2003, issue Ussue 1 2003. Oxford: Update Sftware. Update quaterly..
40. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. B M J 1994;309:1286-91.
41. Grossfeld 1998 Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998;51:137-44.
42. Huggins 1941 Huggins CB, Stevens RB, Hodges CV. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209.
43. Jadad 1996 Jaddad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17((1)):1-12.
44. Labrie 2002 Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized cancer?. Urology 2002;60:115-119.
45. Rambeaud 1999 Rambeaud JJ. Intermittent complete androgen blockade in metastatic prostate cancer. Eur Urol 1999;35((Suppl 1)):32-6.
46. Rennie 1990 Rennie PS, Bruchovsky N, Coldman AJ. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J. Steroid Biochem Mol Biol 1990;37:843-7.
47. Sato 1995 Sato N, Gleave ME, Goldemberg SL. Intermittent androgen suppression delays time to androgen-independent progression in the LN CaP prostate tumor model. J. Urol 1995;153:282a.
48. Waltregny 2002 Waltregny D, Boca P, Nicolas H. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone naïve prostate cancer: results of randomized prospective multicenter clinical trial. Urol 2002;168(A):701.